

Autonomic monitoring

Marek Sykora

St. John's Hospital
SFU Med Vienna, Austria

Agenda

- Meaning of ANS in acute brain injury
- Studies using ICM+ for autonomic assessment

Types of brain injury

Ischemic stroke




ICH +/- IVH



SAH




TBI




Stress and stress-reaction

- Stress is everything what disturbs or endangers *homeostasis*
- ANS, hypothalamic-pituitary-adrenal axis, cardiovascular, metabolic, and immune systems try to maintain “stability through change”
- Adaptive stress-reaction
- Maladaptive stress-reaction



Stress response: a major contributor to harm



Fight-or-flight-or-freeze reaction
 Adrenaline, Cortisole ↑
 Glycogenolysis
 Blood pressure centralisation
 BP, HF ↑
 Bronchodilation
 Leu, Tr ↑
 Thrombogenicity ↑

Arrhytmiae
 Myocardial necrosis
 Endothelial dysfunction
 Insulin resistance, hyperglycemia
 Immunodepression
 Catabolism, end-organ damage
 SIRS, MODS


Central autonomic network

Cortical


Subcortical

Brain stem


Medulla




Central autonomic network



Central autonomic network



Central autonomic disconnection syndrome



↑catecholamines, ↑cortisol, ↑ TNF α , ↑ NPY, ↑ IL1, ↑ IL6 ↑ IL10, insuline resistency, ↑ Glu

Ly-Apoptosis
Th1->Th2 cytokines
↓NK activity
↓ Macrophage activity

Immunusupression

Contraction band necrosis
Myocytolysis
Cross-band formation
Subendocardial hemorrhage

Myocardial damage


IL 6, syst. immfl.
↑ Vessel permeability
Second hit

NPE


Hypoperfusion
↑ Permeability
Endotoxin
Loc. autonomic Dysreg.

Colon paralysis

Extracerebral effects



Cerebral effects (secondary brain injury)



Vasoconstriction

↑ Permeability

Microthrombosis

Hyperglycemia

BBB breakdown

Spleen Tr, systemic IL-1, IL-6, IL-12, TNFalpha

Local inflammation

Immunosuppression

Post-stroke autoimmune response

Autoimmune inflammation

Hypoperfusion

Baroreflex failure

Impaired autoregulation

Impaired CBF

Surrogates of autonomic activity

cardiac derived

HRV

(SDNN, RMSSD)

HF, LF, HF/LF, VLF powers)

BRS

Deceleration capacity

HR turbulence

QT-variability index

HPA derived

AVP, CRH

Cortisol

Catecholamines

Degradation products

Orexin, Urocortins

Copeptin

IS, ICH, IVH, SAB, TBI, GBS, SIRS, MODS, acute MI, HF



↓ Outcome and ↑Mortality
90 days, 6 month, 1 year, 5 years

HRV and BRS in brain injury



IS Colivicchi 2005
Hilz 2011

↓ HF pow
↑ LF pow
↑ LF/HF
↓ BRS




ICH Sykora 2008
Sykora 2018

↑ HF pow
↓ LF pow
↓ LF/HF
↓ BRS



SAH Chiu 2012
Chen 2016
Nasr 2018

↑ HF pow
↓ LF pow
↓ LF/HF
↓ BRS



TBI Sykora 2016
Henden 2014
Biswas 2000


↓(↑) HF pow
↓(↑) LF pow
↑(↓) LF/HF
↓ BRS

↓ Outcome and ↑ Mortality


Autonomic impairment influences outcome

- Cardiac complications und susceptibility to sudden death
- Boost of brain edema und BBB damage
- Blood pressure derrangements und cerebral hypoperfusion
- Stress hyperglycemia
- Immunosupression / Infections



Sympathetic activity in ICP



Baroreflex sensitivity in ICP



Autonomic assessment




ICM+
peak detection
ectopics removal
spectral analysis
cross-correlation
moving window





HRV variability
HF, LF, VLF powers
LF/HF ratio

xBRS

Baroreflex - physiology




Baroreflex sensitivity (xBRS) im ICM+®




The slope of the linear regression between 10s series of RR intervals and 10s series of systolic BP is calculated. The RR window is shifted against the systolic BP in stepwise manner and the highest correlation is reported, if it fulfills the criteria outlined below. Valid BRS value is returned only if the correlation coefficient is significant at $p<0.01$, and if no irregular beats (ectopics) are detected by the software. The BRS is updated every 10s and expressed in ms/mmHg


Baroreflex sensitivity (xBRS) im ICM+®



Baroreflex sensitivity (xBRS) im ICM+®



Baroreflex sensitivity (xBRS) im ICM+®



Autonomic Impairment in Severe Traumatic Brain Injury: A Multimodal Neuromonitoring Study

Marek Sykora, MD, PhD, MSc^{1,2}; Marek Czosnyka, PhD¹; Xiuyun Liu¹; Joseph Donnelly, MBChB¹; Nathalie Nasr, MD, PhD^{1,3}; Jennifer Diedler, MD, MSc⁴; Francois Okoroafor, MD¹; Peter Hutchinson, BSc (hons), MBBS, PhD, FRCS (Surg Neurol)¹; David Menon, MBBS, MD, PhD, FRCP, FRCA, FMedSci⁶; Peter Smielewski, PhD¹

Baroreflex Impairment After Subarachnoid Hemorrhage Is Associated With Unfavorable Outcome

Nathalie Nasr, MD, PhD; Rita Gaio, PhD; Marek Czosnyka, PhD; Karol Budohoski, PhD; Xiuyun Liu, PhD; Joseph Donnelly, PhD; Marek Sykora, MD, PhD; Peter Kirkpatrick, MD, FMedSci; Anne Pavy-Le Traon, MD, PhD; Christina Haubrich, MD, PhD; Vincent Larrue, MD; Peter Smielewski, PhD

Heart rate variability is associated with outcome in spontaneous intracerebral hemorrhage

Jozef Szabo ^a, Peter Smielewski ^b, Marek Czosnyka ^b, Stanislava Jakubicek ^c, Stefan Krebs ^d, Pavel Siarmik ^a, Marek Sykora ^{d,e,*}

Autonomic Impairment in Severe Traumatic Brain Injury: A Multimodal Neuromonitoring Study

- Monocentric, non-randomised comparison
- Cambridge TBI database , n=327, 2003-2009
- Severe TBI, sedated, with ICP monitoring
- xBRS every 10s and HRV every 300s with ICM+
- Adjustment for ICP, CPP und autoregulation (PRx)
- Mortality und Outcome GOS at 6 months

Autonomic Impairment in Severe Traumatic Brain Injury: A Multimodal Neuromonitoring Study


TABLE 1. Comparison of Clinical and Autonomic Variables Between Traumatic Brain Injury Survivors and Nonsurvivors at 6 Months

Variable	Survivors, n = 201	Nonsurvivors, n = 61	p
Age (yr), median (range; IQR)	33 (16–76; 23)	44 (18–76; 32)	< 0.001
Glasgow Coma Scale, median (range; IQR)	7 (3–15)	5 (3–14)	0.072
Intracranial pressure, mm Hg, median (range; IQR)	15.8 (4.5–29.0; 5.6)	17.6 (3.0–50.9; 9.7)	0.002
Cerebral perfusion pressure, mmHg, median (range; IQR)	77.7 (57.7–100.1; 6.6)	74.2 (56.2–102.1; 11.6)	0.002
Pressure reactivity index, median (range; IQR)	0.05 (−0.29–0.70; 0.20)	0.14 (−0.30–0.70; 0.23)	0.002
Baroreflex sensitivity, ms/mm Hg, median (range; IQR)	6.6 (1.6–18.8; 4.2)	5.1 (1.3–18.7; 4.0)	0.026
HF power, ms ² , median (range; IQR)	160.0 (9.9–1853.9; 285.4)	115.0 (6.2–1840.3; 212.1)	0.024
HF relative power, median (range; IQR)	25.8 (5.0–65.4; 17.5)	33.4 (6.6–81.8; 22.3)	< 0.001
LF-to-HF ratio, median (range; IQR)	1.6 (0.2–8.3; 1.3)	1.0 (0.0–8.8; 1.2)	< 0.001
LF power, ms ² , median (range; IQR)	598 (9–133; 927, 1,883)	748 (1–41; 628, 2,291)	0.833
LF relative power, median (range; IQR)	22.1 (7.7–39.5; 7.5)	19.9 (2.6–45.7; 12.1)	0.137
Heart rate variability total power, ms ² , median (range; IQR)	2,551 (90–250; 617, 3,802)	2,169 (56–66; 197; 4,228)	0.701

IQR = interquartile range, HF = high frequency, LF = low frequency.

Variable	Adj OR	95% CI	p
Model for mortality			
BRS, ms/mm Hg	0.888	0.801–0.984	0.024
HF relative power, ms ²	1.046	1.019–1.074	0.001
Age (yr)	1.073	1.046–1.101	< 0.001
Admission GCS	0.800	0.713–0.899	< 0.001
ICP, mm Hg	1.140	1.062–1.225	< 0.001
PRx	11.927	1.559–91.254	0.017
Model for poor outcome			
BRS, ms/mm Hg	0.887	0.804–0.978	0.016
HF relative power, ms ²	1.041	1.015–1.068	0.002
Age (yr)	1.068	1.043–1.095	< 0.001
Admission GCS	0.802	0.718–0.897	< 0.001
ICP, mm Hg	1.132	1.058–1.211	< 0.001
PRx	7.317	1.041–51.420	0.045
Model for unfavorable outcome			
BRS, ms/mm Hg	1.027	1.003–1.051	0.030
HF relative power, ms ²	0.999	0.998–1.000	0.061
Age (yr)	1.058	1.037–1.080	< 0.001
Admission GCS	0.811	0.741–0.888	< 0.001
ICP, mm Hg	1.079	1.017–1.144	0.012

Baroreflex Impairment After Subarachnoid Hemorrhage Is Associated With Unfavorable Outcome




Heart rate variability is associated with outcome in spontaneous intracerebral hemorrhage

Variable	mRS 0–3 at 3 months	mRS 4–6 at 3 months	P
Age mean (range, SD)	59.5 (17–86, 20)	62.2 (34–84, 21)	0.8
Admission NIHSS, median (range, IQR)	5 (1–34, 13)	28 (6–34, 21)	<0.001
Hemorrhage volume median (range, IQR)	14 (1–102, 34)	50 (7–234, 84)	<0.001
Intraventricular extension n (%)	8 (34.8)	18 (75)	0.008
Admission glucose mg/d, median (range, IQR)	113 (89–162, 26)	154 (95–327, 40)	<0.001
HF power, total, ms ² , median (range, IQR)	118 (5–22,588, 263)	55 (5–7458, 343)	0.04
HF power, normalized median (range, IQR)	21 (11–60, 16)	34 (15–83, 16)	0.01
LF power, total, ms ² median (range, IQR)	162 (10–19,060, 262)	24 (2–4704, 178)	0.004
LF power, normalized median (range, IQR)	24 (10–52, 11)	16 (4–46, 14)	0.01
LF/HF ratio median (range, IQR)	1.2 (0.3–4.1, 1)	0.6 (0.05–3, 0.5)	0.003

Variable	Alive at 3 months	Dead at 3 months	P
Age mean (range, SD)	61.3 (17–86, 18)	60.2 (42–84, 13)	0.6
Admission NIHSS, median (range, IQR)	10 (1–34, 18)	34 (11–34, 21)	0.008
Hemorrhage volume median (range, IQR)	36 (1–202, 50)	50 (10–234, 94)	0.03
Intraventricular extension n (%)	15 (43)	11 (92)	0.006
Admission glucose mg/d, median (range, IQR)	124 (89–300, 45)	150 (95–327, 232)	0.04
HF power, total, ms ² , median (range, IQR)	118 (5–22,588, 338)	34 (6–923, 62)	0.01
HF power, normalized median (range, IQR)	27 (11–83, 19)	39 (20–80, 27)	0.04
LF power, total, ms ² median (range, IQR)	153 (2–19,057, 314)	16 (2–283, 22)	0.001
LF power, normalized median (range, IQR)	22 (5–52, 12)	15 (4–37, 10)	0.006
LF/HF ratio median (range, IQR)	0.8 (0.1–4.1, 1)	0.4 (0.05–1, 0.6)	0.02

Future directions – monitoring time trends



Future directions – examining therapies

- BB reduce infarct size and mortality in stroke models (Savitz 2000)
- Pre-stroke BB may have positive outcome effects (n=111, Laowattana 2007)
- BB reduce edema in ICH (Sansing 2011)
- Pre-injury BB reduce stunned myocardium in SAH (Liang 2013)
- BB reduce tissue injury markers and inflammation in SAH (Kawaguchi 2010)
- BB reduce edema in TBI models (Liu 1995)
- Pre-injury BB have positive outcome effects in TBI (Mohseni 2014)
- Post-injury BB have positive outcome effects in TBI

(meta-analysis, n=4782, adjusted OR 0.35; 95 % CI 0.27-0.45, Alali 2014)



Thank you for your attention